The bottom line
Retatrutide's Phase 2 data showed roughly double the weight loss of semaglutide. But semaglutide has years of real-world safety data, is FDA-approved, and is available today. Retatrutide won't be available until 2027 at the earliest.
Semaglutide — the active ingredient in Ozempic and Wegovy — is the most prescribed GLP-1 medication in the United States. It's also the drug that most patients researching retatrutide are either currently taking or considering. This comparison exists because physicians and patients need to understand what the potential advancement represents, and whether it justifies waiting.
The short answer: it doesn't justify waiting, for most people. The longer answer requires understanding what the data actually shows.
Mechanism: GLP-1 Only vs Triple Agonism
Semaglutide is a selective GLP-1 receptor agonist. It achieves its effects — appetite suppression, slowed gastric emptying, blood sugar regulation — through one receptor. The efficacy of this mechanism was considered remarkable when semaglutide received obesity approval in 2021, producing weight loss results that hadn't been achieved pharmacologically before.
Retatrutide keeps GLP-1 receptor activation but adds two more: GIP and glucagon. The glucagon component is the most mechanistically distinct addition — rather than modulating appetite and satiety, it appears to increase energy expenditure at rest and promote fat mobilization directly from adipose tissue.
What the Numbers Say
| Retatrutide (Phase 2) | Semaglutide/Wegovy (Phase 3) | |
|---|---|---|
| Avg weight loss | 24.2% | 14.9% |
| Duration | 48 weeks | 68 weeks |
| Sample size | 338 | 1,961 |
| ≥15% loss | ~67% | ~37% |
| ≥20% loss | ~50% | ~15% |
| Trial phase | Phase 2 | Phase 3 (approved) |
| Available | No | Yes |
The weight loss difference is real and clinically meaningful. But the data context matters: retatrutide's 24.2% is a Phase 2 result in 338 carefully selected patients over 48 weeks. Semaglutide's 14.9% is a Phase 3 result in nearly 2,000 patients over 68 weeks. Phase 2 results routinely look better than Phase 3 results. Retatrutide's Phase 3 results may be lower than 24%.
Semaglutide is available now. Find licensed providers in your state through DawaMed's free quiz.
Get My Match →Safety Profile: Years of Data vs Months
Semaglutide has been in clinical use since 2017 (as Ozempic) and 2021 (as Wegovy). Post-market surveillance now covers millions of patients. The side effect profile — primarily gastrointestinal, primarily during dose escalation — is well-characterized. Long-term cardiovascular data from the SELECT trial (published 2023) showed a 20% reduction in major cardiovascular events in high-risk patients.
Retatrutide has Phase 2 safety data from 338 patients over 48 weeks. Long-term safety at scale — cardiovascular outcomes, bone density effects, lean mass effects over years of use — is unknown.
The Real Question: Should You Wait?
For a patient with metabolic disease, obesity-related comorbidities, or significant weight loss goals: two years of treatment with semaglutide produces real health outcomes. Semaglutide at 15% average weight loss achieves meaningful reductions in blood pressure, fasting glucose, and cardiovascular risk. Waiting for retatrutide means 2+ years without those benefits — and assumes retatrutide's Phase 3 results hold up.
The answer for most patients: start appropriate treatment now, and reassess if and when new options become available.
Read the full retatrutide drug profile, compare retatrutide vs tirzepatide, or return to the future GLP-1 medications hub.
Frequently Asked Questions
How does retatrutide compare to Wegovy for weight loss?
Phase 2 data shows retatrutide produced approximately 24% average weight loss at 48 weeks. Semaglutide (Wegovy) produced approximately 15% average weight loss at 68 weeks in the STEP 1 Phase 3 trial. This is roughly a 9-percentage-point difference, though these are from different trials.
Is retatrutide just a stronger version of Ozempic?
Not quite. Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist. Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The additional receptor targets — especially glucagon — represent mechanistically distinct pathways, not just a dose increase.
When is retatrutide coming out?
Phase 3 TRIUMPH trials are underway with results expected 2025-2026. FDA submission could follow in 2026, with approval possible in 2027. These timelines may shift.
Should I switch from Ozempic to retatrutide when it's available?
That's a decision to make with your prescribing provider when retatrutide becomes available and your clinical situation is assessed. For now, people on semaglutide should continue their current treatment — switching to a non-approved drug isn't possible.
Ready to find your match?
Answer 5 quick questions and see licensed GLP-1 programs available in your state — matched to your budget. Free. No obligation.
Get My Match — Free →